AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03660085 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PC-PEP
Description: The 6 months at home program focuses on aerobic and strength training, pelvic floor muscle exercises, meditation, social connection, and overall healthy lifestyle practices supported with daily text message/email reminders. The aerobic (5 times/week) and strength (2 times/week) program will comprise of a single 30-minute session daily and will be individualized to each participant. Pelvic floor muscle training will include three, 10-minute sessions and mediation for 10 minutes daily. Intimacy and Connection component of PC-PEP consists of engaging in at least one form of intimacy practice prescribed, per day. Social connection will be fostered by pairing participants up with peers from the study. To encourage program compliance, study participants will receive 3 daily reminders to do their pelvic floor muscle exercises per day plus an additional motivational email daily containing helpful tips.
Study NCT03660085 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PC-PEP
Description: The 6 months at home program focuses on aerobic and strength training, pelvic floor muscle exercises, meditation, social connection, and overall healthy lifestyle practices supported with daily text message/email reminders. The aerobic (5 times/week) and strength (2 times/week) program will comprise of a single 30-minute session daily and will be individualized to each participant. Pelvic floor muscle training will include three, 10-minute sessions and mediation for 10 minutes daily. Intimacy and Connection component of PC-PEP consists of engaging in at least one form of intimacy practice prescribed, per day. Social connection will be fostered by pairing participants up with peers from the study. To encourage program compliance, study participants will receive 3 daily reminders to do their pelvic floor muscle exercises per day plus an additional motivational email daily containing helpful tips.
Study NCT04002570 — intervention group
Intervention type: OTHER
Intervention: blood samples collection
Description: blood samples collection are performed at 4 different timepoints: preop, pre rt, week 6 rt, week 12-14 (fu) for GROUP I and GROUP II; blood samples collection are performed at 3 different timepoints: pre rt, week 6 rt, week 12-14 (fu) for GROUP I bis; blood samples collection are performed just once for control GROUP.
Study NCT04139746 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Scleral Buckling
Description: Limbal 360 degrees peritomy of the conjunctiva was performed and the four recti muscles were isolated with 4 silk threads 4-0. A width-2 mm silicone encircling band was placed and sutured with 5-0 mersilene on the 4 quadrants of the sclera. Anterior chamber paracentesis was performed, draining about 0.3 mL of aqueous humour, and a buckle (220, 501, 506, or 516; Mira, Waltham, MA, USA) was sutured over the break. In all cases, the drainage puncture was executed at a distance of 11 mm from the limbus, in the area of greatest amount of subretinal fluid. Soon after the drainage puncture, a balanced salt solution (BSS) injection was performed in order to compensate the escape of the subretinal fluid.
Study NCT04139746 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Drainage-Injection-Pneumoretinopexy
Description: According to the location of the sub-retinal fluid, a quadrant-flap of conjunctiva was opened. Indirect ophthalmoscopy evaluation was also used intraoperatively to localize the break and the subretinal fluid drainage site: in this area a vicryl 6-0 thread was passed through the sclera, about 9-10 mm posteriorly from the limbus, to facilitate the surgical maneuvers. The drainage puncture was performed 11 mm posteriorly from the limbus, having attention not to perform it directly above the site of the retinal break. In detail, a 2 mm radial sclera incision was created with a 15° disposable knife. The incision was cautiously deepened down to the choroid, which was finally perforated by a lachrymal dilator having a blunt tip. Soon after beginning the subretinal fluid drainage, an injection of BSS was performed in the opposite quadrant of the sclera (4 mm from the limbus) in order to allow an optimal spillage of the subretinal fluid and to flatten the retina.
Study NCT03306797 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: STANDARD REHAB
Description: The rehabilitative standard intervention (Occupational Therapy) consists of 15 minutes of warm-up exercises plus a 20 minutes training with at least 6 exercises selected from:~wrist~* ulnarization radialization~* prono-supination~* horizontal flexion-extension~* vertical flexion-extension hand~* grasping~* pinching~* extensors~* interosseous shoulder-elbow~* vertical flexion-extension~* push forward
Study NCT03306797 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SONICHAND
Description: The intervention is similar to the standard protocol (15 minutes of warm-up plus 20 minute of training) but involves the sonification of the exercises selected from the list. The Leap Motion Controller is managed with an ad-hoc developed application that is able to associate the movements with a 4 notes arpeggio or with a modulated texture.~With the first mode the movement produces and modulates an harmonic progression built on the consecutive grades of the major scale played as ascending and descending arpeggio with also a volume crescendo and decrescendo.~With the second mode, the movement modulates the volume and the low-pass cutoff frequency of a synthetic texture.
Study NCT03021174 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EXCAP Exercise
Description: 12 weeks of at-home walking and resistance exercise
Study NCT03021174 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nutrition Education Control
Description: 12 weeks of implementing eating tips
Study NCT01594437 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TCN-202
Description: Human monoclonal neutralizing antibody that recognizes a broadly conserved functional epitope on HCMV. One or two doses will be administered by intravenous infusion.
Study NCT01594437 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One or two doses administered by intravenous infusion.
Study NCT05184751 — intervention group
Intervention type: OTHER
Intervention: colonoscopy
Study NCT03218683 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5991
Description: AZD5991 will be administered intravenously for 9 cycles (each cycle 21 days) or until patient derives treatment benefit or progresses
Study NCT03218683 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5991 + Venetoclax
Description: Ascending oral doses of AZD5991 and/or venetoclax until no longer tolerated or disease progression
Study NCT03652922 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Reactivation Mismatch
Description: Ninety minutes prior to each of six weekly traumatic memory reactivation sessions, the subject will be given 0.67 mg/kg of short-acting propranolol (or placebo), rounded up to the nearest 10 mg (minimum 40 mg) and 1 mg/kg of oral long-acting propranolol or placebo (minimum 60 mg). rounded so as to achieve a dose of 60, 80, 120, or 160 mg. The subject will then read a narrative of their personal traumatic event aloud. During each weekly reading, a simple, different mismatch condition will be created by having the subject do such things as whisper the narrative, skip over every word that contains the letter e, pronounce the narrative in a different accent, or alter the tense and/or person of the narrative.
Study NCT03652922 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reactivation Mismatch
Description: Ninety minutes prior to each of six weekly traumatic memory reactivation sessions, the subject will be given 0.67 mg/kg of short-acting propranolol (or placebo), rounded up to the nearest 10 mg (minimum 40 mg) and 1 mg/kg of oral long-acting propranolol or placebo (minimum 60 mg). rounded so as to achieve a dose of 60, 80, 120, or 160 mg. The subject will then read a narrative of their personal traumatic event aloud. During each weekly reading, a simple, different mismatch condition will be created by having the subject do such things as whisper the narrative, skip over every word that contains the letter e, pronounce the narrative in a different accent, or alter the tense and/or person of the narrative.
Study NCT00201539 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: single dose Morphine
Study NCT00201539 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: double dose Morphine
Study NCT00201539 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: purchased from the manufacturer of morphine tablets (Nycomed Pharma, Oslo, Norway)
Study NCT00503399 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teriparatide
Description: 20 µg/day sc for 18 months
Study NCT00503399 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risedronate
Description: 35 mg/week po for 18 months
Study NCT00982566 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-263
Description: Part 1: Single (oral) dose of 250 mg of Formulation B1 vs. single (oral) dose of 250 mg of Formulation A
Study NCT00982566 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-263
Description: Part 1 continued. Single (oral) dose of 250 mg of Formulation B2 vs. single (oral) dose of 250 mg of Formulation A
Study NCT00982566 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-263
Description: Part 1: Single (oral) dose of 200 mg of Formulation C vs. single (oral) dose of 200 mg of Formulation A
Study NCT04394741 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intervention-Dry Needling
Description: Deep Dry Needling into the site of the latent Trigger Point of the upper trapezius muscle.~1 session in upper trapezius muscle moving the needle up and down ten times.
Study NCT04394741 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Intervention-Dry Needling
Description: Deep Dry Needling into the site of the latent Trigger Point of the upper trapezius muscle.~1 session in upper trapezius muscle moving the needle up and down ten times.
Study NCT04394741 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Control-Dry Needling
Description: Sham Dry Needling into the site of the latent Trigger Point of the upper trapezius muscle with non-penetrating needles~1 session in upper trapezius muscle moving the needle up and down ten times.
Study NCT02826148 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: RAADS-R scale
Description: This scale is a self-administered questionnaire completed by the person himself assisted by a clinician
Study NCT00862953 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Normal protein energy-restricted
Description: Normal protein diet energy restricted
Study NCT00862953 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Normal protein energy-restricted
Description: Normal protein diet energy restricted
Study NCT00862953 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High protein energy-restricted
Description: High protein diet, with either low or normal carbohydrate content
Study NCT01713517 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Indoor residual insecticide spraying (IRS)
Description: Application of insecticide to interior walls of domiciliary structures to kill malaria vector mosquitoes which rest on walls after taking human blood meal
Study NCT02965118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PAC-14028 cream 1.0%
Description: topical application
Study NCT02965118 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PAC-14028 cream Vehicle
Description: topical application
Study NCT00287248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [123I] IMPY & SPECT Imaging
Description: Subjects will be injected with 7mCi of \[123I\]IMPY, followed by SPECT imaging
Study NCT01993537 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Study NCT01366651 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doripenem
Description: Type=exact number, unit=mg/kg, number=30, form=solution for injection, route=intravenous use, every 8 hours for 2 days (total of 5 doses) for patients 12 weeks to \<1 year of age.
Study NCT01366651 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doripenem
Description: Type=exact number, unit=mg/kg, number=10, form=solution for injection, route=intravenous use, every 8 hours for 2 days (total of 5 doses) for patients \<12 weeks of age.
Study NCT01313923 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus (formerly known as Rapamycin)
Description: For low to moderate immunologic risk, the loading dose is 6mg immediately after transplantation, followed by 2mg PO Qday in conjunction with cyclosporine and corticosteroids. After 2-4 months, cyclosporine should be discontinued over 4-8 weeks while titrating sirolimus drug concentrations within the target-range with whole blood trough concentrations every 1-2 weeks. Monitoring is needed because cyclosporine inhibits the metabolism of sirolimus, and discontinuation of cyclosporine can lead to lower levels of sirolimus. In high immunologic risk patients, the loading dose is 15mg after transplantation, followed by 5mg PO Qday in conjunction with cyclosporine and corticosteroids for 12 months. A whole blood trough level is recommended between days 5 and 7 with adjustment to the daily dose.
Study NCT03675841 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazufloxacin Mesilate ear drops
Description: Pazufloxacin Mesilate ear drops of 0.1%，0.3%，0.5%
Study NCT04336423 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Obtain samples from sputum and feces
Description: Samples are obtained from participants. No further intervention is required. Obtained samples will be further analyzed.
Study NCT01713517 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Long Lasting Insecticidal Nets (LLIN)
Description: Provision of LLIN to all community members in the clusters allocated to the study arm. LLIN protect individuals from bites by malaria vector mosquitoes by providing a physical barrier and insecticidal and repellent effect.
Study NCT01713517 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Long Lasting Insecticidal Nets (LLIN)
Description: Provision of LLIN to all community members in the clusters allocated to the study arm. LLIN protect individuals from bites by malaria vector mosquitoes by providing a physical barrier and insecticidal and repellent effect.
Study NCT02742688 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pyrus pyrifolia var. culta(Makino) NaKai peel extract
Description: Pyrus pyrifolia var. culta(Makino) NaKai peel extract(4g/day)
Study NCT02742688 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo(4g/day)
Study NCT00376844 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: External Beam Radiation Therapy
Study NCT00376844 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Vaginal Brachytherapy
Study NCT00143507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivabradine
Study NCT03417882 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GRN-1201 + Pembrolizumab
Description: GRN-1201 will be administered in combination with Pembrolizumab
Study NCT00789074 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Varenicline
Description: Varenicline 1mg twice daily
Study NCT00789074 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: Varenicline 1mg twice daily
Study NCT00789074 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 1mg BD
Study NCT03674931 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: musical practice
Description: Intensive weekly musical keyboard training over 12 months
Study NCT03674931 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: music education
Description: Recreative weekly musical courses without practice over 12 months
Study NCT00531687 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Paclitaxel
Description: Paclitaxel 175 mg/m2 day 1 (3 hour infusion)~Repeat at 21-day intervals for 4 cycles if toxicity is acceptable. If necessary more than 4 cycles can be administered.
Study NCT00531687 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Cisplatin
Description: cisplatin 50 mg/m2 day 1 and 2~Repeat at 21-day intervals for 4 cycles if toxicity is acceptable. If necessary more than 4 cycles can be administered.
Study NCT00531687 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Gemcitabine
Description: gemcitabine 1000mg/m2 days 1 and 8 (in a 30 minute infusion)~Repeat at 21-day intervals for 4 cycles if toxicity is acceptable. If necessary more than 4 cycles can be administered
Study NCT02208401 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional cold snare polypectomy
Description: conventional cold snare polypectomy
Study NCT02208401 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cold snare polypectomy with suction
Description: Cold snare polypectomy with suction
Study NCT01974765 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: All enrolled patients will be treated with enzalutamide 160mg by mouth QD. Study drugs will be self-administered by patients. A cycle is 28 days.
Study NCT01407003 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LIK066
Description: Participants will receive a single or multiple doses of LIK066
Study NCT01407003 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive a single or multiple doses of a matching placebo
Study NCT01915927 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: MSC-AFP
Study NCT02605837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Budesonide Suspension (OBS)
Description: Oral Budesonide Suspension (OBS) 10 milliliter (ml) of 0.2 milligram per milliliter (mg/ml) twice daily up to 16 weeks.
Study NCT02605837 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral dose of 10 ml of placebo matched with the experimental drug.
Study NCT00762424 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flowmax
Description: 0.4 mg once a day until stone passage total = 9 tablets
Study NCT00762424 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: cornstarch
Study NCT01546402 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone Drug delivery system (Ozurdex)
Description: It is a sustained release intravitreal implant containing 700µg dexamethasone has been approved by the US-FDA (Food and Drug Administration).
Study NCT01546402 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cataract surgery
Description: Using a clear corneal incision, continuous curvilinear capsulorhexis, hydrodissection, phacoemulsification and irrigation/aspiration of the cortex will be performed. Foldable intraocular lens will be implanted in the capsular bag. All patients will receive standard postoperative topical steroid (betamethasone 0.1%), antibiotic (moxifloxacin 0.5%) and homatropine (2%) therapy.
Study NCT01284049 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intralipid 20%®
Description: Administration of Intralipid 20%® at a dose ranging between 0.5 and 1 g/kg/infusion during 12 weeks.
Study NCT01284049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OMEGAVEN 10%®
Description: OMEGAVEN 10%® will be used as the sole lipid supplement at a dose of 0.5 to 1.0 g/kg/Infusion with a maximum dose per infusion of 40 grams, in view of formulation constraints during 12 weeks.
Study NCT02054481 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 655066
Description: Medium dose
Study NCT02054481 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 655066
Description: High dose
Study NCT02054481 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ustekinumab
Study NCT02054481 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 655066
Description: Low dose
Study NCT00912665 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser Doppler Flowmetry
Description: blood flow measurements at the temporal neuroretinal rim to assess optic nerve head blood flow
Study NCT00912665 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Goldmann applanation tonometer
Description: intraocular pressure measurements
Study NCT00912665 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: squatting
Description: Subjects will perform squatting for 6 minutes while either blood flow or intraocular pressure measurements
Study NCT00912665 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Suction cup
Description: Experimental stepwise increase of intraocular pressure while either optic nerve head blood flow or intraocular pressure measurements
Study NCT05173545 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone Hydrochloride Liposome Injection
Description: Every 28 days is a administration cycle, a total of 4 cycles.Until the subject's PD or intolerable or withdrawal (whichever occurs first).~5% Glucose Injection drugs dissolved in 250 ml, intravenous drip for 60 minutes.
Study NCT00852332 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Curcumin
Study NCT00852332 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taxotere
Study NCT00852332 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Taxotere